Plasma lyso-Gb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes

被引：1
|
作者：
Nowak, Albina [1 ]
Mechtler, Thomas P. [2 ]
Desnick, Robert J. [3 ]
Kasper, David C. [4 ]
机构：
[1] Univ Zurich Hosp, Zurich, Switzerland
[2] Univ Hosp Zurich, Vienna, Austria
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] ARCHIMED Life Sci, Vienna, Austria
来源：
MOLECULAR GENETICS AND METABOLISM | 2017年 / 120卷 / 1-2期
关键词：
Biomarker; Fabry disease; Heterozygotes; LysoGb3; α-galactosidase deficiency;
D O I：
10.1016/j.ymgme.2016.11.262
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
253
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [21] Lyso-Gb3 activates Notch1 in human podocytes
    Sanchez-Nino, Maria D.
    Carpio, Daniel
    Belen Sanz, Ana
    Ruiz-Ortega, Marta
    Mezzano, Sergio
    Ortiz, Alberto
    HUMAN MOLECULAR GENETICS, 2015, 24 (20) : 5720 - 5732
  • [22] The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain
    Choi, L.
    Vernon, J.
    Kopach, O.
    Mitlett, M. S.
    Mills, K.
    Clayton, P. T.
    Meert, T.
    Wood, J. N.
    NEUROSCIENCE LETTERS, 2015, 594 : 163 - 168
  • [23] Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation
    Chien, Yin-Hsiu
    Bodamer, Olaf A.
    Chiang, Shu-Chuan
    Mascher, Hermann
    Hung, Christina
    Hwu, Wuh-Liang
    JOURNAL OF INHERITED METABOLIC DISEASE, 2013, 36 (05) : 881 - 885
  • [24] Lyso-Gb3 modulates the gut microbiota and decreases butyrate production
    Aguilera-Correa, John-Jairo
    Madrazo-Clemente, Patricia
    del Carmen Martinez-Cuesta, Maria
    Pelaez, Carmen
    Ortiz, Alberto
    Dolores Sanchez-Nino, Maria
    Esteban, Jaime
    Requena, Teresa
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [25] Is globotriaosylceramide a useful biomarker in Fabry disease?
    Young, E
    Mills, K
    Morris, P
    Vellodi, A
    Lee, P
    Waldek, S
    Winchester, B
    ACTA PAEDIATRICA, 2005, 94 : 51 - 54
  • [26] Plasma globotriaosylsphingosine as a biomarker of Fabry disease
    Togawa, Tadayasu
    Kodama, Takashi
    Suzuki, Toshihiro
    Sugawara, Kanako
    Tsukimura, Takahiro
    Ohashi, Toya
    Ishige, Nobuyuki
    Suzuki, Ken
    Kitagawa, Teruo
    Sakuraba, Hitoshi
    MOLECULAR GENETICS AND METABOLISM, 2010, 100 (03) : 257 - 261
  • [27] Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
    Giuffrida, Gaetano
    Markovic, Uros
    Condorelli, Annalisa
    Calafiore, Valeria
    Nicolosi, Daniela
    Calagna, Marianna
    Grasso, Stephanie
    Ragusa, Marco Tindaro Valentino
    Gentile, Jennifer
    Napolitano, Mariasanta
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
  • [28] Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
    Gaetano Giuffrida
    Uros Markovic
    Annalisa Condorelli
    Valeria Calafiore
    Daniela Nicolosi
    Marianna Calagna
    Stephanie Grasso
    Marco Tindaro Valentino Ragusa
    Jennifer Gentile
    Mariasanta Napolitano
    Orphanet Journal of Rare Diseases, 18
  • [29] An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: Utility for Fabry disease diagnosis and treatment monitoring
    Rozenfeld, Paula A.
    De Francesco, Nicolas P.
    Borrajo, Gustavo J. C.
    Ceci, Romina
    Fossati, Carlos A.
    CLINICA CHIMICA ACTA, 2009, 403 (1-2) : 194 - 197
  • [30] Fabry disease: Diagnosis and treatment
    Breunig, F
    Weidemann, F
    Beer, M
    Eggert, A
    Krane, V
    Spindler, M
    Sandstede, J
    Strotmann, J
    Wanner, C
    KIDNEY INTERNATIONAL, 2003, 63 : S181 - S185
12345